Gelonghui, January 30丨Nanxin Pharmaceutical (688189.SH) announced the 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected that net profit attributable to owners of the parent company in 2023 will turn a loss into a profit compared with the same period last year, and achieve net profit attributable to the owners of the parent company of 200,000 yuan to 10 million yuan. The net profit attributable to the owners of the parent company after deducting non-recurring profit and loss for the year 2023 is expected to be -5 million yuan to 5 million yuan.